ReviewOncology reviews2014
Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.
Review in Oncology reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- Novel seleno-ureido hybrids targeting head and neck cancer and beyond: design, synthesis, and apoptosis-mediated anticancer evaluation.RSC advances · 2026Article
- Multi-omics dissection of RAD21-PON1 axis reveals metabolic-immune crosstalk and prognostic significance in hepatocellular carcinoma.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- The Beneficial Effects of Resveratrol on Hepatocellular Carcinoma and Nonalcoholic Fatty Liver Disease: Modulation of Apoptosis, Autophagy, Inflammation, and Oxidative Stress.Food science & nutrition · 2025Review
- Diterpenoids from the Aerial Parts ofMolecules (Basel, Switzerland) · 2024Article
- Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells.Cell death discovery · 2024Article
- Comparison of Engineered Liver 3D Models and the Role of Oxygenation for Patient-Derived Tumor Cells and Immortalized Cell Lines Cocultured with Tumor Stroma in the Detection of Hepatotoxins.Advanced biology · 2024Article
- Therapeutic options in hepatocellular carcinoma: a comprehensive review.Clinical and experimental medicine · 2023Review
- Article
- Design, Synthesis, and Biological Evaluation of Novel Hydroxamic Acid-Based Organoselenium Hybrids.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Enhancement of treatment efficacy of hepatic tumours using Trans-arterial-chemoembolization.American journal of cancer research · 2023Review
- Anticancer, Antimicrobial, and Antioxidant Activities of Organodiselenide-Tethered Methyl Anthranilates.Biomolecules · 2022Article
- Oncopharmacology in Interventional Radiology.Seminars in interventional radiology · 2022Review
- Novel Organoselenium Redox Modulators with Potential Anticancer, Antimicrobial, and Antioxidant Activities.Antioxidants (Basel, Switzerland) · 2022Article
- Article
- Chitosan Containing Nano Zn-Organic Framework: Synthesis, Characterization and Biological Activity.Polymers · 2022Article
- A Competition between Hydrogen, Stacking, and Halogen Bonding inInternational journal of molecular sciences · 2022Article
- Article
- The Role of Ferroptosis in the Treatment and Drug Resistance of Hepatocellular Carcinoma.Frontiers in cell and developmental biology · 2022Review
- Extraction and Purification of R-Phycoerythrin Alpha Subunit from the Marine Red AlgaeMolecules (Basel, Switzerland) · 2021Article
- Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.Hepatology (Baltimore, Md.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a dreaded malignancy that every year causes half a million deaths worldwide. Being an aggressive cancer, its incidence exceeds 700,000 new cases per year worldwide with a median survival of 6-8 months. Despite advances in prognosis and early detection, effective HCC chemoprevention or treatment strategies are still lacking, therefore its dismal survival rate remains largely unchanged. This review will characterize currently available chemotherapeutic drugs used in the treatment of HCC. The respective mode(s) of action, side effects and recommendations will be also described for each drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.